p16 mutation frequency and clinical correlation in head and neck cancer

Acta Oto-Laryngologica

Volumn 119, Issue 2, 1999, Pages 285-288

  Danahey, Daniel G ^a   Tobin, Evan J ^a   Schuller, David E ^a   Bier Laning, Carol M ^a   Weghorst, Christopher M ^a   Lang, Jas C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Head and neck cancer; p16; RB; RT PCR; Tumor suppressor

Indexed keywords

PROTEIN P16;

ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; GENE DELETION; GENE INSERTION; GENE MUTATION; HEAD CANCER; HUMAN; HUMAN TISSUE; NECK CANCER; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

EID: 0032946062     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016489950181837     Document Type: Article

References (25)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-30.
2. Yoo GH, Xu JJ, Brennan JA, et al. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 1994; 54: 4603-6.
3. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4: 1463-8.
4. Lucas JM, Mountain RE, Gramza AW, Schuller DE, Wilkie NM, Lang JC. Expression of cyclin D1 in squamous cell carcinomas of the head and neck. Int J Oncol 1994; 5: 469-72.
5. Field JK, Spandidos DA, Donckerwolcke RA. Overexpression of p53 gene in head and neck cancer, linked with heavy smoking and drinking. Lancet 1992; 339: 502-3.
6. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
7. Ink4. Cancer Res 1994; 54: 5816-20.
8. Ink4 CDK inhibitory activity. Int J Cancer 1996; 66: 249-54.
9. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-40.
10. Mori T, Kiura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/ CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396-7.
11. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
12. Ink4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995; 55: 1436-40.
13. Ink4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505-9.
14. Zhang S-Y, Klein-Szanto A, Sauter ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994; 54: 5050-3.
15. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3.
16. Olshan AF, Weissler MC, Pei H, et al. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 1997; 14: 811-8.
17. Lang JC, Tobin EJ, Knobloch TJ, et al. Frequent mutation of p16 in squamous cell carcinoma of the head and neck. Laryngoscope 1998; 108: 923-8.
18. INK4a gene inactivation by deletions, mutations and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-84.
19. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995; 85: 2685-90.
20. INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997; 74: 57-63.
21. INK4A expression of nonsmall cell lung carcinoma. Cancer 1997; 80: 389-95.
22. Lydiatt WM, Davidson BJ, Schantz S, Caruana S, Chaganti RSK. 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck 1998; 20: 113-8.
23. Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713-8.
24. Gramza AW, Lucas JM, Mountain RE, Schuller DE, Lang JC. Efficient method for preparing normal and tumor tissue for RNA extraction. BioTechniques 1995; 18: 228-9.
25. Okamoto A, Demetrick DJ, Spillare EA, et al. p16INK4 mutations and altered expression in human tumors and cell lines. Cold Spring Harbor Symp Quant Biol 1994; 59: 49-57.